Your browser is no longer supported. Please, upgrade your browser.
Settings
ARNA Arena Pharmaceuticals, Inc. daily Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.01 Insider Own0.10% Shs Outstand48.83M Perf Week0.72%
Market Cap2.18B Forward P/E- EPS next Y-3.45 Insider Trans-38.06% Shs Float48.83M Perf Month-9.90%
Income-103.60M PEG- EPS next Q-0.64 Inst Own80.20% Short Float7.04% Perf Quarter20.36%
Sales16.50M P/S131.90 EPS this Y-484.40% Inst Trans0.43% Short Ratio4.97 Perf Half Y31.55%
Book/sh14.60 P/B3.05 EPS next Y-17.70% ROA-25.90% Target Price61.89 Perf Year85.25%
Cash/sh12.88 P/C3.46 EPS next 5Y- ROE-37.10% 52W Range20.02 - 50.05 Perf YTD31.20%
Dividend- P/FCF- EPS past 5Y8.60% ROI-34.20% 52W High-12.00% Beta1.60
Dividend %- Quick Ratio- Sales past 5Y-5.00% Gross Margin66.40% 52W Low120.00% ATR1.32
Employees159 Current Ratio15.30 Sales Q/Q5.90% Oper. Margin- RSI (14)45.12 Volatility2.27% 3.55%
OptionableYes Debt/Eq0.10 EPS Q/Q13.80% Profit Margin- Rel Volume0.62 Prev Close44.57
ShortableYes LT Debt/Eq0.10 EarningsAug 07 BMO Payout- Avg Volume691.37K Price44.04
Recom1.80 SMA20-0.95% SMA50-3.56% SMA20018.53% Volume147,059 Change-1.18%
May-31-18Initiated RBC Capital Mkts Outperform $65
Mar-21-18Upgrade Needham Hold → Buy $60
Mar-20-18Reiterated JMP Securities Mkt Outperform $63 → $79
Jan-18-18Resumed Credit Suisse Outperform $44
Jan-18-18Initiated Credit Suisse Outperform $44
Jan-03-18Upgrade Wells Fargo Market Perform → Outperform
Jul-11-17Reiterated Citigroup Buy $23 → $37
Jul-07-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jun-27-17Initiated Citigroup Buy $23
May-19-17Initiated Leerink Partners Outperform $5
Sep-15-16Initiated FBR & Co. Outperform $6
Mar-01-16Reiterated RBC Capital Mkts Sector Perform $2 → $1.50
Nov-11-15Reiterated RBC Capital Mkts Sector Perform $5 → $2
Oct-28-15Reiterated WallachBeth Buy $6 → $4
May-12-15Reiterated WallachBeth Buy $8 → $6
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Jul-12-18 07:15AM  Free Pre-Market Technical Recap on ArQule and Three Additional Biotech ACCESSWIRE
Jul-10-18 08:30AM  Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors PR Newswire
Jul-02-18 08:20AM  Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Arena Pharmaceuticals ACCESSWIRE
07:30AM  A Savvy Biotech Investor Is Betting Up To $25 Million Dollars On This $8 Stock Returning 250%... Or More? ACCESSWIRE
Jun-20-18 02:45PM  Is Arena Pharmaceuticals Inc (NASDAQ:ARNA) As Strong As Its Balance Sheet Indicates? Simply Wall St.
Jun-13-18 07:25AM  Initiating Free Research Reports on ArQule and Three Other Biotech Equities ACCESSWIRE
Jun-12-18 01:35PM  Will the Market Go Dead for a While? TheStreet.com
Jun-07-18 09:05AM  Arena Pharmaceuticals (ARNA) Up 15.1% Since Earnings Report: Can It Continue? Zacks
Jun-01-18 08:30AM  Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Seattle Genetics ACCESSWIRE +5.16%
May-21-18 08:30AM  Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference PR Newswire
May-17-18 11:17AM  Small-Caps Are the Place to Be for Now TheStreet.com
May-15-18 08:10AM  Report: Developing Opportunities within Haemonetics, Arena Pharmaceuticals, Xperi, MoneyGram International, Boot Barn, and Green Dot Future Expectations, Projections Moving into 2018 GlobeNewswire
May-11-18 12:25PM  Having Some Good Luck With Biotech Names TheStreet.com
May-10-18 08:30AM  Arena Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
May-09-18 01:52PM  Markets Make an Art of Unpredictability TheStreet.com
01:46PM  Edited Transcript of ARNA earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
10:38AM  Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected Zacks
May-08-18 04:01PM  Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results PR Newswire
May-07-18 08:30AM  Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More Zacks
May-06-18 06:19PM  The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More Benzinga
May-03-18 08:30AM  Today's Research Reports on Trending Tickers: Insmed and Arena Pharmaceuticals ACCESSWIRE
May-02-18 08:30AM  Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8 PR Newswire +5.58%
May-01-18 11:08AM  What's in the Cards for Arena (ARNA) This Earnings Season? Zacks
08:30AM  Arena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound PR Newswire
Apr-26-18 07:08PM  Cramer's lightning round: Now is the time to buy Walgreen... CNBC Videos
Apr-21-18 07:16AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Apr-18-18 08:30AM  Todays Research Reports on Trending Tickers: GW Pharmaceuticals and Arena Pharmaceuticals ACCESSWIRE +5.73%
Apr-17-18 02:45PM  Arena CEO: We have two great assets and are trying to bui... CNBC Videos +7.96%
Apr-13-18 09:57AM  Arena Pharmaceuticals (ARNA) Up 7% Since Earnings Report: Can It Continue? Zacks
Apr-12-18 08:30AM  Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting PR Newswire
Apr-05-18 08:05AM  This $3 Medical Device Stock be Worth $9-14 with Impending Product Launch ACCESSWIRE
Mar-29-18 12:39PM  Arena Pharmaceuticals Inc (NASDAQ:ARNA): Earnings Growth Remains Elusive Simply Wall St.
Mar-26-18 04:15PM  Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
11:00AM  This Obesity Drugmaker Just Made a Comeback While Another Declared Bankruptcy Motley Fool
Mar-24-18 09:32AM  3 Biotech Stocks That Skyrocketed This Week: Are They Buys? Motley Fool
Mar-23-18 07:30PM  Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27 PR Newswire
06:00PM  Arena Pharmaceuticals Takes Aim at Celgene Motley Fool
Mar-22-18 04:58PM  One Biotech Turnaround to Watch Motley Fool -6.41%
08:41AM  Arena Pharmaceuticals (ARNA) in Focus: Stock Moves 10.7% Higher Zacks
Mar-21-18 07:07PM  Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire +10.69%
04:30PM  Why Whiting Petroleum, Arena Pharmaceuticals, and First Majestic Silver Jumped Today Motley Fool
03:24PM  Here's Why Arena Pharmaceuticals, Inc. Surged Again on Wednesday Motley Fool
10:39AM  Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene Zacks
10:29AM  Company News For Mar 21, 2018 Zacks
08:10AM  Todays Research Reports on Trending Tickers: Arena Pharmaceuticals and CASI Pharmaceuticals ACCESSWIRE
Mar-20-18 05:08PM  What Happened in the Stock Market Today Motley Fool +28.68%
04:22PM  Arena Pharmaceuticals shares tick lower on secondary offering MarketWatch
04:16PM  Biotech Stock Jumps By A Third As Rivalry With Celgene Heats Investor's Business Daily
04:01PM  Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
01:42PM  Why Arena Pharmaceuticals Shares Are Rocketing 31.6% Higher Today Motley Fool
11:43AM  Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal Zacks
07:56AM  Arena Pharmaceuticals' stock rockets after positive drug trial results MarketWatch
07:00AM  Arena Pharmaceuticals Takes a Big Step Forward Motley Fool
Mar-19-18 05:13PM  Arena Pharma Rockets Nearly 30% On Ulcerative Colitis Trial Investor's Business Daily
05:02PM  Higher dose of Arena Pharma's bowel disease drug meets study goal Reuters
04:01PM  Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis PR Newswire
Mar-15-18 03:26PM  Arena Pharmaceuticals (ARNA) Q4 2017 Earnings Conference Call Transcript Motley Fool -8.38%
10:45AM  Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y Zacks
08:41AM  Options Traders Expect Huge Moves in Arena Pharmaceuticals (ARNA) Stock Zacks
04:58AM  Edited Transcript of ARNA earnings conference call or presentation 14-Mar-18 12:30pm GMT Thomson Reuters StreetEvents
Mar-14-18 09:42AM  Arena (ARNA) Posts Narrower-Than-Expected Q4 Loss, Shares Up Zacks -8.27%
08:00AM  Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results PR Newswire
Mar-13-18 07:50AM  Arena Pharmaceuticals Q4 Earnings Preview Benzinga
Mar-08-18 08:30AM  Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2017 Financial Results and Provide Corporate Update on Wednesday, March 14 PR Newswire
Mar-06-18 10:16AM  What's in the Cards for Arena (ARNA) This Earnings Season? Zacks
Mar-01-18 08:30AM  Arena Pharmaceuticals to Present Phase 1 and Preclinical Data on APD371 in Development for Treatment of Pain Associated with Crohn's Disease at American Pain Society Annual Scientific Summit PR Newswire
Feb-28-18 08:00AM  Benzinga Pro's 5 Stocks To Watch Benzinga
Feb-20-18 08:16PM  Zogenix Inc. (ZGNX) and Arena Pharmaceuticals, Inc. (ARNA) Helped This Healthcare-Focused Fund Earn Double-Digit Returns Insider Monkey
Feb-16-18 08:30AM  Arena Pharmaceuticals Announces Changes to Board of Directors PR Newswire
Feb-14-18 08:31AM  Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter Motley Fool
Feb-09-18 08:30AM  Todays Research Reports on Trending Tickers: Arena Pharmaceuticals and VIVUS ACCESSWIRE
Feb-06-18 04:30PM  Arena Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
Feb-02-18 02:19PM  Arena Pharmaceuticals Inc (NASDAQ:ARNA): Is Healthcare Attractive Relative To NasdaqGS Peers? Simply Wall St.
Jan-31-18 07:40AM  Analysis: Positioning to Benefit within Alliqua BioMedical, Donegal Group, QAD, ManpowerGroup, Acorda Therapeutics, and Arena Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-22-18 05:04PM  Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City PR Newswire
Jan-15-18 01:09PM  Three Interviews From the J.P. Morgan Healthcare Conference Motley Fool
Jan-03-18 04:47PM  Arena Pharma Upgraded Ahead Of Clinical Data Release Benzinga +10.94%
12:36PM  TODAY'S CHARTS: MoneyGram plunges on blocked deal; IBM gets an upgrade; AMD soars on Intel 'design flaw' Yahoo Finance
Dec-25-17 09:23AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-21-17 08:30AM  Arena Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 10 PR Newswire +5.51%
Dec-18-17 06:35PM  Does Arena Pharmaceuticals Incs (NASDAQ:ARNA) 67.6% EPS Growth Reflect The Long-Term Trend? Simply Wall St.
Dec-11-17 11:19AM  Here's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November Motley Fool
Dec-05-17 08:30AM  Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China PR Newswire
Nov-27-17 07:50AM  Market Trends Toward New Normal in Arena Pharmaceuticals, National Fuel Gas, Capitol Federal Financial, Comfort Systems, National Instruments, and Navistar International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-22-17 08:09AM  Should You Buy Arena Pharmaceuticals Inc (ARNA) At $27.23? Simply Wall St.
Nov-16-17 12:28PM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : November 16, 2017 Capital Cube
Nov-15-17 07:50AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : November 15, 2017 Capital Cube
Nov-13-17 10:40AM  Edited Transcript of ARNA earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
09:44AM  Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study Zacks
Nov-10-17 11:31AM  Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis PR Newswire
Nov-08-17 09:53AM  Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat Zacks -6.92%
Nov-07-17 04:51PM  Arena Pharmaceuticals reports 3Q loss Associated Press
04:01PM  Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results PR Newswire
02:18PM  The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October Motley Fool
09:39AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : November 7, 2017 Capital Cube
Oct-31-17 08:30AM  Arena Pharmaceuticals to Present at the Credit Suisse Healthcare Conference on November 8 PR Newswire
Oct-30-17 05:51PM  What's in the Cards for Arena (ARNA) This Earnings Season? Zacks
08:30AM  Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7 PR Newswire
Oct-27-17 10:44AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : October 27, 2017 Capital Cube
Oct-19-17 08:30AM  Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting PR Newswire
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangitis and pyoderma gangrenosum; and APD371, which is in Phase II trial for the treatment of pain associated with Crohn's disease. The company has collaboration agreements with Everest Medicines Limited; Axovant Sciences GmbH; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPECTOR STEVEN WEVP, General Counsel & SecApr 16Option Exercise18.0030,001540,01849,691Apr 18 05:31 PM
SPECTOR STEVEN WEVP, General Counsel & SecApr 16Sale34.5730,0011,037,05819,690Apr 18 05:31 PM